Since early TGF-β signature HCC models are expected to be sensitive to TGF-β antiproliferative effects but not late TGF-β signature models, we tested TGF-β growth inhibition on our 7 cell lines (Figure 1C-1E). Here, TGFB1 is linked to hepatocellular carcinoma.